Scott Swain details the most common roadblocks that pharma companies experience when incorporating real-world data (RWD) in regulatory submissions and looks at how they can be addressed.
Scott Swain, PhD, MPH
Advertisement
Articles by Scott Swain, PhD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials
3
Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq
4
Redefining Medical Strategy in Obesity Through Real-World iNSIGHTS
5